<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947216</url>
  </required_header>
  <id_info>
    <org_study_id>6398</org_study_id>
    <nct_id>NCT03947216</nct_id>
  </id_info>
  <brief_title>Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.</brief_title>
  <acronym>PIMPARK</acronym>
  <official_title>Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NS-PARK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EUCLID Clinical Trial Platform</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>F-CRIN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no consensus on the treatment of Impulse Control Disorder (ICD) in Parkinson Disease&#xD;
      (PD) though it is recommended to reduce the dosage of dopamine agonists (DA).&#xD;
&#xD;
      Reduction of DA frequently leads to a worsening of motor signs (parkinsonism or dyskinesias&#xD;
      due to the concomitant increase of levodopa doses) and non-motor signs with the appearance of&#xD;
      a DA withdrawal syndrome (DAWS).&#xD;
&#xD;
      Chronic stimulation of the sub-thalamic nuclei may reduce ICD but is restricted to a minority&#xD;
      of patients and cases of new-onset ICD symptoms post stimulation have been reported. The&#xD;
      benefit of amantadine in pathological gambling is controversial and the efficacy of clozapine&#xD;
      has been reported in a few cases but with serious safety limitations. Very recently,&#xD;
      naltrexone did not significantly improve ICD.&#xD;
&#xD;
      Thus, an efficacious and safe treatment of ICD in PD remains an unmet need for clinical&#xD;
      practice.&#xD;
&#xD;
      Recently, it has been reported that pimavanserin, a selective serotonin 5-HT2A inverse&#xD;
      agonist with a satisfactory safety profile without motor side effects, was efficient in&#xD;
      improving psychosis, insomnia and day-time sleep in PD.&#xD;
&#xD;
      Pimavanserin, marketed under the tradename NUPLAZID® was approved in 2016 by the U.S. Food&#xD;
      and Drug Administration (FDA) for the treatment of hallucinations and delusions associated&#xD;
      with Parkinson's disease psychosis.&#xD;
&#xD;
      The link between serotonin and ICD has been well established, since the enhancement of 5HT2A&#xD;
      receptors stimulation is associated to ICD, since serotonin modulates mesolimbic dopaminergic&#xD;
      reward system transmission and given that serotonin neurotransmission is increased during&#xD;
      chronic intake of dopamine agonist such as pramipexole which is well-known to induce ICD in&#xD;
      PD patients. Thus, there is a large body of evidence suggesting that the decrease of the&#xD;
      5HT2A activity could be efficient in reducing ICD in PD. This further supports the concept of&#xD;
      testing the efficacy of pimavanserin (a selective 5HT2A inverse agonist) for treating ICD in&#xD;
      PD. Our aim is to conduct a study evaluating the efficacy and safety of pimavanserin on ICD&#xD;
      in PD.&#xD;
&#xD;
      This clinical trial is conducted with the support of the French NS-Park/FCRIN (French&#xD;
      Clinical Research Infrastructure Network) network.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ICD (Impulsive Control Disorders) severity after 8 weeks of treatment evaluated by QUestionnaire for Impulse-compulsive disorder in Parkinson's disease Rating Scale (QUIP-RS).</measure>
    <time_frame>at day 0 and week 8</time_frame>
    <description>The primary endpoint of this study will be assessed in both arms using the total form of QUIP-RS.&#xD;
QUIP-RS has 4 primary questions (pertaining to commonly reported thoughts, urges/desires, and behaviors associated with ICDs), each applied to the 4 ICDs (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). It uses a 5-point Likert scale (score 0-4 for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16 and the total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112, with a higher score indicating greater severity (ie, frequency) of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change SCale for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP) score after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>The SCOPA-SLEEP is a specific Parkinson's disease rating scale for assessing nighttime sleep (NS) problems and daytime sleepiness (DS) in the past month. The NS subscale has 5 items, scored from 0 (not at all) to 3 (a lot). The DS subscale is composed of 6 items with response options ranging from 0 (never) to 3 (often) with a higher total score indicating greater severity of sleep problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Movement Disorders Society-sponsored Unified Parkinson's Disease Rating scale (MDS-UPDRS) scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor Complications. The four parts contains 64 items which are each rated on a scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Negative changes from baseline values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60 with higher MADRS score indicating more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ardouin's scale scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>The Ardouin's scale is a validated instrument using a structured and standardised interview composed of 21 items specifically designed to assess mood and behaviour with a view to quantifying changes related to Parkinson's Disease, to dopaminergic medication, and to non-motor fluctuations. Each item is scored from 0 (absent) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the rate of Clinical Global Impression Severity (CGIS) scale after 4, 8 and 16 weeks of treatment</measure>
    <time_frame>At day 0, week 4, week 8 and week 16</time_frame>
    <description>Severity of PD will be assessed in both arms using CGIS scale: the CGI-S is a 7-point scale that requires the rating of the severity of the patient's illness at the time of assessment. Possible ratings are: 1: Normal, not at all ill; 2: Borderline mentally ill; 3: Mildly ill; 4: Moderately ill ; 5: Markedly ill; 6: Severely ill; 7: Among the most extremely ill patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ICD (Impulsive Control Disorders) severity after 4 weeks of treatment evaluated by QUIP-RS.</measure>
    <time_frame>At day 0 and week 4</time_frame>
    <description>Global functioning and severity of the disease will be assessed in both arms by QUIP-RS has 4 primary questions each applied to the 4 ICDs and 3 related disorders It uses a 5-point Likert scale and a higher score indicating greater severity (ie, frequency) of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life measured by Parkinson's Disease Questionnaire (PDQ-39) scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>Functioning and well-being of patients during the preceding month will be assessed in both arms by 39 questions of the self-administered Parkinson's Disease Questionnaire (PQD-39). Each question is scored from 0 (never) to 4 (always), the higher score indicating higher impact of illness in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Zarit scale scores after 4 and 8 weeks of treatment for caregivers</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>The burden of the patient's functional and behavioural worsening and to home care will be assessed to the caregiver in both arms by the Zarit Burden scale. It is composed of 22 items to measure the magnitude of the burden experienced by the caregiver. Each item is scored from 0 (never) to 4 (almost always). With a higher score indicating a greater load suffered by the caregiver.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total number of adverse events and serious adverse events</measure>
    <time_frame>At week 16</time_frame>
    <description>Open-ended questionnaire will be used in both arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active drug: pimavanserin 17mg (2 strength tablets)</intervention_name>
    <description>Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: 2 tablets containing same excipients except active compound</intervention_name>
    <description>Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of severity of ICD (impulse control disorders)</intervention_name>
    <description>Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors</intervention_name>
    <description>Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of quality of life</intervention_name>
    <description>Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of depression</intervention_name>
    <description>Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of cognition</intervention_name>
    <description>Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of severity of Parkinson Disease</intervention_name>
    <description>Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood analysis</intervention_name>
    <description>Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac monitoring</intervention_name>
    <description>Electrocardiogram will be realized at day 0, 28 and 56.</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with PD according to the UKPDSBB criteria for at least 1 year before&#xD;
             randomization&#xD;
&#xD;
          2. Patient, man or woman, aged from 35 to 75 years old&#xD;
&#xD;
          3. Patient with moderately severe ICD assessed by QUIP-RS (each item being rated 0-16)&#xD;
             defined as:&#xD;
&#xD;
               -  a combined ICD total score (defined as the sum of the 4 ICD sub-scores&#xD;
                  (pathological gambling + buying + hypersexuality + eating)) superior or equal to&#xD;
                  10 or,&#xD;
&#xD;
               -  at least one of the 4 ICD sub-scores in the following range:&#xD;
&#xD;
                    1. &quot;pathological gambling&quot; sub-score from 6 to 12 (included),&#xD;
&#xD;
                    2. &quot;buying&quot; sub-score from 8 to 12 (included),&#xD;
&#xD;
                    3. &quot;hypersexuality&quot; sub-score from 8 to 12 (included),&#xD;
&#xD;
                    4. &quot;eating&quot; sub-score from 7 to 12 (included) (Weintraub et al., 2012). The use&#xD;
                       of &quot;lower&quot; margins will guarantee that the patient experiences behavioral&#xD;
                       disturbances severe enough to justify pimavanserin treatment. On the other&#xD;
                       hand, the use of &quot;upper&quot; margins will guarantee that the patients included&#xD;
                       in the trial will not suffer from ICD severe enough to question ethically&#xD;
                       the use of placebo during the 8 weeks of the treatment. Eligibility of&#xD;
                       patients with QUIP-RS sub-scores above 12 will be assessed upon&#xD;
                       investigator's request by an adjudication committee composed by independent&#xD;
                       experts external to the study (cf IX.3 Adjudication Committee).&#xD;
&#xD;
          4. ICD onset after PD onset and after initiation of dopaminergic drugs&#xD;
&#xD;
          5. Patient treated by dopaminergic drugs for at least 3 months before randomization&#xD;
&#xD;
          6. Patient treated with a stable regimen of levodopa, dopamine agonists, COMT and MAOB&#xD;
             inhibitors, amantadine, anticholinergic, antidepressant and benzodiazepine for at&#xD;
             least 1 month before the randomization and be willing to remain on the same doses&#xD;
             throughout the course of their participation in the trial (Papay et al., 2014)&#xD;
&#xD;
          7. Patient with health insurance&#xD;
&#xD;
          8. Patient/ guardian / curator who sign the written informed consent&#xD;
&#xD;
          9. For women of childbearing potential, use of an effective contraception method* for at&#xD;
             least 1 month prior to randomization until 8 weeks after the last dose of study drug&#xD;
             administration. Women who do not have an effective contraception* must : have had her&#xD;
             last natural menstruation ≥24 months prior to the selection visit, or have been&#xD;
             surgically sterilized prior to the selection visit, or have had a hysterectomy prior&#xD;
             to the selection visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient suffering from another parkinsonian syndrome (multiple system atrophy,&#xD;
             progressive supranuclear palsy, Lewy body dementia, corticobasal degeneration)&#xD;
&#xD;
          2. Patient who have a known hypersensitivity to the study treatment, based on known&#xD;
             allergies to drugs of the same class&#xD;
&#xD;
          3. Stroke, uncontrolled serious medical illness, myocardial infarction, congestive heart&#xD;
             failure, cardiac function disorders, within 6 months before randomization&#xD;
&#xD;
          4. Patient with history of long QT syndrome&#xD;
&#xD;
          5. Patient with long QTcB detected with ECG at inclusion visit (&gt; 450 ms)&#xD;
&#xD;
          6. Patient treated with antipsychotic drugs during the last three months before&#xD;
             randomization&#xD;
&#xD;
          7. Patient treated with concomitant medication leading to torsade de pointes (TdP)&#xD;
             without discontinuation ≥ 5 half-lives before randomization (please refer to&#xD;
             medications list with known risks of TdP on appendix XVII.5.10 and check website&#xD;
             https://crediblemeds.org/index.php/tools/ for the most up-to-date information)&#xD;
&#xD;
          8. Patient with hydro-electrolytics troubles, particularly hypokaliemia or hypocalcemia&#xD;
             not corrected, at inclusion visit or assessed no later than 8 days before&#xD;
             randomization&#xD;
&#xD;
          9. Patient treated with a strong or moderate CYP3A4 inducer: carbamazepine, rifampicin,&#xD;
             phenytoin, modafinil, efavirenz or a strong inhibitor of CYP3A4: azole antifungals,&#xD;
             protease inhibitors, macrolids, without discontinuation ≥ 5 half-lives before&#xD;
             randomization&#xD;
&#xD;
         10. Patient treated with medicinal plants interacting with CYP3A4 without discontinuation&#xD;
             ≥ 5 half-lives before randomization (Echinacea (E.pupurea, E.angustifolia and&#xD;
             E.pallida), Piperina, Artemisia, St. John's Wort and Ginkgo&#xD;
&#xD;
         11. Patient with Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score &lt; 20&#xD;
             (to exclude patients likely with dementia) at inclusion visit (Papay et al., 2014).&#xD;
&#xD;
         12. Patient suffering from severe depression or marked suicidal thoughts (score &gt; 3 on the&#xD;
             suicidal thoughts item of the MADRS) at inclusion visit (Papay et al., 2014)&#xD;
&#xD;
         13. History of DBS within the past year before randomization, or change in stimulation&#xD;
             parameters less than one month prior to randomization&#xD;
&#xD;
         14. Hematologic or solid malignancy diagnosis within 5 years prior to randomization.&#xD;
&#xD;
             [Note: Subjects with a history of localized skin cancer, basal cell or squamous cell&#xD;
             carcinoma, may be enrolled in the study as long as they are cancer free prior to&#xD;
             randomization. Subjects with other localized cancers (without metastatic spread) who&#xD;
             have previously completed their course of treatment more than 5 years prior to&#xD;
             randomization, are not currently receiving treatment and have been in remission may be&#xD;
             enrolled only if, in the opinion of the Investigator, there is no expectation for&#xD;
             recurrence or further cancer treatment during the study period. Antihormonal therapy&#xD;
             (e.g., tamoxifen) is allowed if the subject's cancer is in remission and the subject&#xD;
             is on stable maintenance therapy to reduce their risk of recurrence.]&#xD;
&#xD;
         15. Patient suffering from severe renal impairment define as CrCL&lt;30 mL/min,&#xD;
             Cockcroft-Gault at inclusion visit or assessed no later than 8 days before&#xD;
             randomization&#xD;
&#xD;
         16. Clinically significant hepatic impairment&#xD;
&#xD;
         17. Current participation in another research involving human beings of category 1 or 2&#xD;
&#xD;
         18. Patient with language barriers precluding adequate understanding or co-operation or&#xD;
             who, in the opinion of the investigator, should not participate in the trial&#xD;
&#xD;
         19. Treatment with an investigational treatment within 30 days prior to randomization&#xD;
&#xD;
         20. Woman pregnant, nursing or of childbearing potential age without effective&#xD;
             contraception methods* or intends to become pregnant.&#xD;
&#xD;
               -  an effective contraception method is defined as implants, oral&#xD;
                  oestro-progestative contraceptives or progestative which inhibit ovulation&#xD;
                  contraceptives (e.g, desogestrel), or double barrier method (condom plus&#xD;
                  spermicide or diaphragm plus spermicide) or levonorgestrel intrauterine devices,&#xD;
                  or vasectomized partner (confirmed with two negative spermograms).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu ANHEIM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu ANHEIM, MD</last_name>
    <phone>+33 3 88 12 85 35</phone>
    <email>mathieu.anheim@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier RASCOL, MD</last_name>
    <phone>+33 5 61 14 59 62</phone>
    <email>olivier.rascol@univ-tlse3.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Neurologie -CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthieu BEREAU, MD</last_name>
      <phone>+33 3 81 66 86 55</phone>
      <email>mbereau@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Matthieu BEREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE C, Unité mouvement anormaux/Centre expert Parkinson, CHU de Lyon, Hopital neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloé LAURENCIN, MD</last_name>
      <phone>33 4 72 35 72 35</phone>
      <email>chloe.laurencin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Chloé LAURENCIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson CHU Clermont-Ferrand, Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck DURIF, MD</last_name>
      <phone>33 4 73 75 22 00</phone>
      <email>fdurif@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Franck DURIF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe REMY, MD</last_name>
      <phone>+33 1 49 81 43 53</phone>
      <email>neuro-philippe.remy@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe REMY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie FRAIX, MD</last_name>
      <phone>+33 4 76 76 94 52</phone>
      <email>vfraix@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie FRAIX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, CHU de Lille, Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc DEFEBVRE, MD</last_name>
      <phone>+33 3 20 44 67 30</phone>
      <email>Luc.DEFEBVRE@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Luc DEFEBVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc HOUETO, MD</last_name>
      <phone>+33 5 55 05 65 60</phone>
      <email>jean-luc.houeto@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc HOUETO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe AZULAY, MD</last_name>
      <phone>+33 4 91 38 43 33</phone>
      <email>Jean-philippe.AZULAY@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe AZULAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Nantes, Hopital Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiphaine ROUAUD, MD</last_name>
      <phone>+33 2 40 16 52 86</phone>
      <email>Tiphaine.Rouaud@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Tiphaine ROUAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE Centre Expert Parkinson Hopital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe CORVOL, MD</last_name>
      <phone>+33 1 42 16 57 66</phone>
      <email>jean-christophe.corvol@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe CORVOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Inverstigation Clinique, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle BENATRU, MD</last_name>
      <phone>+33 5 49 44 44 46</phone>
      <email>isabelle.benatru@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc HOUETO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DOE DE MAINDREVILLE, MD</last_name>
      <email>adoedemaindreville@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DOE DE MAINDREVILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rennes, Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie DRAPIER, MD</last_name>
      <phone>+33 2 99 28 42 93</phone>
      <email>Sophie.Drapier@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie DRAPIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rouen, Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MALTETE, MD</last_name>
      <phone>+33 2 32 88 87 40</phone>
      <email>david.maltete@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>David MALTETE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE Unité de Mouvements Anormaux/Centre expert Parkinson, CHU de Strasbourg, Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu ANHEIM, MD</last_name>
      <phone>+33 3 88 12 85 35</phone>
      <email>mathieu.anheim@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu ANHEIM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Toulouse, Hopital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier RASCOL, MD</last_name>
      <phone>+33 5 61 14 59 62</phone>
      <email>olivier.rascol@univ-tlse3.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier RASCOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impulse control disorders</keyword>
  <keyword>pimavanserin</keyword>
  <keyword>Serotoninergic 5-HT2A inverse agonist</keyword>
  <keyword>Dopamine agonist</keyword>
  <keyword>Behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

